Full FDA approval for Travere’s Filspari

San Diego, USA-based Travere Therapeutics (Nasdaq: TVTX) saw its shares close up more than 8% at $10.75 yesterday on positive news form the US regulator.

The Food and Drug Administration (FDA) has granted full approval to Filspari (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression.

As part of the conversion Thursday, the FDA has removed a specific urine protein level requirement from Filspari’s label, which will allow Filspari to reach more patients. Now, the only condition for treatment with Filspari is that patients be at risk of disease progression.